Chairman of the Board of Directors and Chief Executive Officer
Patrick Alexandre is the founder of Crossject and chairman of its Executive Board. He is a graduate of Supélec and was an R&D manager in the steel industry for 10 years before joining the pharmaceutical industry where he worked for 15 years. In 1997, Patrick Alexandre began directing the conceptualization and development of needleless injection technology at Laboratoires Fournier now Abbvie, and in 2001, he built upon that acquired expertise to launch Crossject. Patrick Alexandre remains the CEO of Crossject and was named as Chairman of the company's Executive Board in 2012.
Chief Operating Officer Specialty Pharma
Olivier Giré is a graduate of EDHEC business school and joined Crossject in 2016 with more than 20 years of experience in the pharmaceutical industry. He created and managed commercial affiliates with more than 200 employees and international networks of more than 50 distributors in around 50 countries during his time at such international groups as IPSEN, where he worked for 12 years, but also at AMDIPHARM and EXELTIS. Olivier Giré has in-depth expertise in the launch of innovative medicines and the management of pharmaceutical products in dozens of therapeutic specialties.
Chief Quality and Regulatory Officer
When Isabelle Liebschütz, Doctor in Pharmacy, joined Crossject in 2013, she brought more than 17 years of experience in the pharmaceutical industry. For five years, she worked within the formulations and development team at Laboratoires Fournier (now Abbvie), and for seven years, she was a quality assurance manager for transdermal systems, subcontracted products and quality systems for the European and American markets within the Fournier / Solvay Group.
Between 2008 and 2013, Isabelle Liebschütz held the post of chief pharmacist at a CMO specialized in the industrialization and manufacturing of pharmaceutical products and medical devices.
Henri de Parseval
Chief Operating Officer Engineering & Industry
Henri de Parseval holds a diploma from the Ecole Nationale Supérieure des Arts et Métiers Paris Tech and brought to Crossject more than 17 years of experience in supply chain management. He developed his expertise in the management of strategic partnerships, purchasing, and materials flow while working in several international groups. His last mission, carried out for important mining groups, was the creation of an entire supply chain to enable the deployment of innovative railway safety systems in Australia.
Henri de Parseval has overseen restructuration projects and coordinated operations at the international level in highly competitive sectors. He has also acquired in-depth knowledge on managing supplier performance in demanding regulatory settings.
Chairman of the board
Philippe is the co-owner of private equity firm Gemmes Venture, which he co-founded in 1999. Gemmes Venture has been a founding partner in numerous companies in healthcare (Asten Santé, H2AD telehealth, VivaLib,…), Digital services, Fin Tech, and Clean Tech. Gemmes Venture has been Crossject’s first and main shareholder. Philippe Monnot graduated from EM LYON.
Patrice Coissac has been Corporate SVP of Alexion & President of Alexion International Sarl, based in Lausanne since April 2009 until March 2013. He previously founded Alexion Europe SAS in Paris and served as President from November 2005 until March 2009. Under his leadership, the company has expanded considerably across Europe, Middle-East and Africa allowing many patients suffering from ultra-rare diseases in this region to have access to therapy.
Prior to joining Alexion, Patrice Coissac held various high level positions with leading pharmaceutical companies in Western Europe, Switzerland and Japan. Patrice Coissac offers a wealth of international experience which he gained during his extensive exposure to global health care matters and pharmaceutical business challenges.
Dr. Jean-Francois Loumeau
Dr. Jean-Francois Loumeau practiced medicine (1981 to 1985) and then held numerous positions in the pharmaceutical industry in France and internationally, particularly in commercial, business developement or subsidiary management positions from 1985 to 2005.
He was a Director on the supervisory board of a French pharmaceutical contract manufacturing organisation from 2007 to 2013. Since then he has held various non-executive director positions in several pharmaceutical companies in France and in Europe as well as advisor to private equity funds in LBO transactions involving pharmaceutical production sites and product portfolios.
He recently joined the advisory board of E-Sana, a young French start-up specialized in ultraportable point of care diagnostic kits.
Dr. Jean-Francois Loumeau graduated from the Faculty of Medicine Paris VI - University Pierre and Marie Curie. He is also a graduate of the ESSEC Business School (1985).
Eric is a professional investor, senior adviser to STEED Capital, and created Maceninvest1 a business angels fund, after a career in banking and finance. He was a member of Deutsche Bank’s Executive Committee in France, the CEO of Banque Worms as well as Detroyat Associes, after working at Banque Stern and Banexi. Eric Nemeth started his career in the Saint-Gobain group, where he was, among several assignments, head of corporate finance and investor relations from 1982 to 1989.
Dr Yannick Plétan
Dr Yannick PLÉTAN first practiced medicine (Head of Ward Respiratory – Menton Hospital) and participated in numerous research projects with INSERM (Institut National de la Santé et de la Recherche Médicale). Then, he held senior executive roles in the pharmaceutical industry for over 20 years (SANOFI, Pierre Fabre Research Institute, Pfizer, Roche) during which he successfully launched several products.He now advises innovative biotech companies in Europe and the US on development strategy or regulatory and medical approach.
The employee representatives on the Supervisory Board are Carole CAUCASE and Frédéric MEUGNIER.